These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 22328117)

  • 21. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis.
    Cotté FE; Fardellone P; Mercier F; Gaudin AF; Roux C
    Osteoporos Int; 2010 Jan; 21(1):145-55. PubMed ID: 19459025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
    Body JJ; Lichinitser M; Tjulandin S; Garnero P; Bergström B
    Ann Oncol; 2007 Jul; 18(7):1165-71. PubMed ID: 17442659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis.
    Curtis JR; Xi J; Westfall AO; Cheng H; Lyles K; Saag KG; Delzell E
    Med Care; 2009 Mar; 47(3):334-41. PubMed ID: 19194337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous bisphosphonates for post-menopausal osteoporosis: adherence to a network guideline.
    Yeh Y; Slovik D; Carter D; Clapp M; Churchill W; Reddy P
    J Clin Pharm Ther; 2011 Jun; 36(3):342-7. PubMed ID: 21545613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fractures and mortality in relation to different osteoporosis treatments.
    Yun H; Delzell E; Saag KG; Kilgore ML; Morrisey MA; Muntner P; Matthews R; Guo L; Wright N; Smith W; Colón-Emeric C; O'Connor CM; Lyles KW; Curtis JR
    Clin Exp Rheumatol; 2015; 33(3):302-9. PubMed ID: 25068266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of monthly intravenous ibandronate on the low responders to oral bisphosphonate: the MOVEMENT study.
    Hagino H; Sakai A; Ikeda S; Imanishi Y; Tsurukami H; Nakajo S; Miyakoshi N
    J Bone Miner Metab; 2019 Nov; 37(6):1013-1023. PubMed ID: 31098670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries.
    Yun H; Curtis JR; Guo L; Kilgore M; Muntner P; Saag K; Matthews R; Morrisey M; Wright NC; Becker DJ; Delzell E
    BMC Musculoskelet Disord; 2014 Apr; 15():112. PubMed ID: 24684864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M; Viapiana O; Gatti D; Adami S
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.
    Gold DT; Alexander IM; Ettinger MP
    Ann Pharmacother; 2006 Jun; 40(6):1143-50. PubMed ID: 16735667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.
    Bianchi G; Czerwinski E; Kenwright A; Burdeska A; Recker RR; Felsenberg D
    Osteoporos Int; 2012 Jun; 23(6):1769-78. PubMed ID: 21975558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens.
    Epstein S
    Curr Osteoporos Rep; 2006 Mar; 4(1):14-20. PubMed ID: 16527003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of osteoporosis in the aging male: focus on zoledronic acid.
    Piper PK; Gruntmanis U
    Clin Interv Aging; 2009; 4():289-303. PubMed ID: 19750231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.
    Nakamura T; Ito M; Hashimoto J; Shinomiya K; Asao Y; Katsumata K; Hagino H; Inoue T; Nakano T; Mizunuma H;
    Osteoporos Int; 2015 Nov; 26(11):2685-93. PubMed ID: 26001561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
    Petranova T; Boyanov M; Shinkov A; Petkova R; Intorcia M; Psachoulia E
    Arch Osteoporos; 2017 Dec; 13(1):1. PubMed ID: 29264666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diffuse ocular and orbital inflammation after zoledronate infusion-case report and review of the literature.
    Umunakwe OC; Herren D; Kim SJ; Kohanim S
    Digit J Ophthalmol; 2017; 23(4):18-21. PubMed ID: 29403337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States.
    Durden E; Pinto L; Lopez-Gonzalez L; Juneau P; Barron R
    Arch Osteoporos; 2017 Dec; 12(1):22. PubMed ID: 28243883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.
    Li M; Xing XP; Zhang ZL; Liu JL; Zhang ZL; Liu DG; Xia WB; Meng XW
    J Bone Miner Metab; 2010 May; 28(3):299-305. PubMed ID: 19855926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass.
    Hadji P; Ziller V; Gamerdinger D; Spieler W; Articus K; Baier M; Moericke R; Kann PH
    Osteoporos Int; 2012 Jul; 23(7):2043-51. PubMed ID: 22086310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan.
    Lin SY; Chen YM; Chen WJ; Li CY; Ku CK; Chen CH; Chien LN
    Arch Osteoporos; 2022 Jul; 17(1):94. PubMed ID: 35840845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.